Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679621 | 1.00 | CES1 (0.50) | CES1SMN1; SMN2MAPK1HTTNPC1 | |
| SCHEMBL28514598 | 0.83 | SMN1; SMN2 (0.46) | CES1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL2782446 | 0.82 | PLA2G2D (0.41) | CES1SMN1; SMN2MAPK1HTTALDH1A1 | |
| SCHEMBL29857544 | 0.78 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL26054307 | 0.78 | NPC1 (0.45) | SMN1; SMN2HTTNPC1RAB9AALDH1A1 | |
| SCHEMBL14215786 | 0.78 | MAPT (0.56) | CES1MAPK1HTTALDH1A1LMNA | |
| SCHEMBL17441862 | 0.76 | MAPK1 (0.49) | CES1MAPK1HTTALDH1A1LMNA | |
| SCHEMBL361933 | 0.76 | CES1 (0.60) | CES1SMN1; SMN2MAPK1HTTNPC1 | |
| SCHEMBL7630857 | 0.76 | KDM4E (0.54) | CES1SMN1; SMN2MAPK1HTTNPC1 | |
| SCHEMBL1791035 | 0.76 | ALDH1A1 (0.64) | CES1SMN1; SMN2MAPK1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| CN-108912020-A | Ao Dangka is replaced and its preparation method of intermediate | 上海博志研新药物技术有限公司 | 2018-11-30 | — | — | CN | claimed |
| CN-108250109-A | A kind of synthetic method of substituted biphenyl compound | 苏州科伦药物研究有限公司 | 2018-07-06 | — | — | CN | claimed |
| CN-105175583-B | Acetophenones light trigger, preparation method and applications of one class with biphenyl as conjugated structure | 同济大学 | 2017-06-13 | — | — | CN | claimed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11440892-B2 | Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis | NORTHWESTERN UNIVERSITY (US) | 2022-09-13 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| CN-105175583-B | Acetophenones light trigger, preparation method and applications of one class with biphenyl as conjugated structure | 同济大学 | 2017-06-13 | — | — | CN | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| CN-105153329-B | Acetophenone type photoinitiators using fluorene as conjugated structure as well as preparation method and application of acetophenone type photoinitiators | 同济大学 | 2017-03-22 | — | — | CN | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | CES1 1932/4885SMN1; SMN2 1505/4885MAPK1 1856/4885 |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CES1 495/4885SMN1; SMN2 3998/4885MAPK1 1325/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CES1 495/4885SMN1; SMN2 3998/4885MAPK1 1325/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | CES1 495/4885SMN1; SMN2 3998/4885MAPK1 1325/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CES1 495/4885SMN1; SMN2 3998/4885MAPK1 1325/4885 |
| US-20250340516-A1 | Isoquinolinones as Modulators of POLRMT | POLRMT, TFAM, UQCRC1 | CES1 1363/4885SMN1; SMN2 2390/4885MAPK1 3713/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | CES1 2029/4885SMN1; SMN2 2828/4885MAPK1 2734/4885 |
| US-11440892-B2 | Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis | NQO1, DHPS, NQO2 | CES1 1436/4885SMN1; SMN2 3673/4885MAPK1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.